Floatz logo

AZD9291

EGFR-TKI Resistant Mutation

Shandong Cancer Hospital and InstituteSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the EGFR-TKI Resistant Mutation cohort.

Asset / SponsorPhaseRating
Osimertinib
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
DALPICICLIB ISETIONATE
Tianjin Medical University Cancer Institute and Hospital
Phase 2CCC
Silevertinib
Black Diamond Therapeutics, Inc.
Phase 1/2CC
Nintedanib
China Medical University Hospital
Phase 1/2CC
Gefetinib
China Medical University Hospital
Phase 1/2CC

Same molecule, other indications

AZD9291 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
AZD9291Dormant
B
Indicative ·
60 / 100
View asset →
Non Small Cell Lung CancerDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →